TapewireFind a company

person · Reporting owner

Cox Christopher Nixon

Disclosed activity across 3 companies

Tapewire entity
45308
SEC CIK
0002008212

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Alto Neuroscience, Inc.ANRO · Entity 4755DirectorMay 12, 2026May 14, 2026
High-Trend International GroupHTCO · Entity 7566DirectorMarch 07, 2026March 16, 2026
Newsmax Inc.NMAX · Entity 789DirectorMay 20, 2026May 21, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Alto Neuroscience, Inc.

Report date May 12, 2026 · Filed May 14, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.63 · Expires 2036-05-11Direct10,958 Reported balance After 2026-05-12 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-05-12 · Grant · Acquired 10,958 · Balance 10,958

F2: This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy, and was not sold to the Reporting Person. As such, the Reporting person did not pay any consideration for the derivative securities.

F1: The shares underlying the option shall vest on the earlier of the one-year anniversary of the date of grant and the date of Issuer's next Annual Meeting following the date of grant, subject to the Reporting Person's continuous service through such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares underlying the option shall vest on the earlier of the one-year anniversary of the date of grant and the date of Issuer's next Annual Meeting following the date of grant, subject to the Reporting Person's continuous service through such vesting date.

F2: This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy, and was not sold to the Reporting Person. As such, the Reporting person did not pay any consideration for the derivative securities.

High-Trend International Group

Report date March 07, 2026 · Filed March 16, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Options on HTCO Class A Ordinary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $8.27 · Expires 2036-03-07DirectNot disclosed Reported balance Holding disclosure · report date 2026-03-07 · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · Balance Not disclosed

Stock Options on HTCO Class A Ordinary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $8.27 · Expires 2036-12-10IndirectUnvestedNot disclosed Reported balance Holding disclosure · report date 2026-03-07 · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · Balance Not disclosed

Stock Options on HTCO Class A Ordinary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $8.27 · Expires 2037-12-10IndirectUnvestedNot disclosed Reported balance Holding disclosure · report date 2026-03-07 · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · Balance Not disclosed

Newsmax Inc.

Report date May 20, 2026 · Filed May 21, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.31 · Expires 0036-05-20Direct23,940 Reported balance After 2026-05-20 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-05-20 · Grant · Acquired 23,940 · Balance 23,940

F1: The option was granted pursuant to the Issuer's 2025 Omnibus Equity Incentive Plan and a Stock Option Grant Notice and Option Agreement. The option shall become exercisable on the 12-month anniversary of the grant date, provided that the Reporting Person continues to provide services to the Issuer through such date.

Filing footnotes · ownership attribution and instrument terms

F1: The option was granted pursuant to the Issuer's 2025 Omnibus Equity Incentive Plan and a Stock Option Grant Notice and Option Agreement. The option shall become exercisable on the 12-month anniversary of the grant date, provided that the Reporting Person continues to provide services to the Issuer through such date.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
May 20, 2026 Filed May 21, 2026 20:57 UTC Newsmax Inc. NMAX · Entity 789 GrantOption (Right to Buy) · Derivative 23,940 $0.00 Strike: $7.31 $0.00
Disclosure

SEC source: 0001628280-26-037364 · wk-form4_1779397037.xml · derivative · entry 1

Cox Christopher Nixon · CIK 0002008212 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,940

Underlying: Class B Common Stock · 23,940 shares

Expires 0036-05-20

F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's 2025 Omnibus Equity Incentive Plan and a Stock Option Grant Notice and Option Agreement. The option shall become exercisable on the 12-month anniversary of the grant date, provided that the Reporting Person continues to provide services to the Issuer through such date.

Read SEC document
May 12, 2026 Filed May 14, 2026 20:58 UTC Alto Neuroscience, Inc. ANRO · Entity 4755 GrantStock Option (right to buy) · Derivative 10,958 $0.00 Strike: $24.63 $0.00
Disclosure

SEC source: 0002008212-26-000004 · wk-form4_1778792320.xml · derivative · entry 1

Cox Christopher Nixon · CIK 0002008212 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,958

Underlying: Common Stock · 10,958 shares

Expires 2036-05-11

F2 · price: This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy, and was not sold to the Reporting Person. As such, the Reporting person did not pay any consideration for the derivative securities.

F1 · derivative.exercise_date: The shares underlying the option shall vest on the earlier of the one-year anniversary of the date of grant and the date of Issuer's next Annual Meeting following the date of grant, subject to the Reporting Person's continuous service through such vesting date.

Read SEC document
January 02, 2026 Filed Jan 6, 2026 21:47 UTC Alto Neuroscience, Inc. ANRO · Entity 4755 GrantStock Option (right to buy) · Derivative 7,189 $11.82 Strike: $16.59 $84,973.98
Disclosure

SEC source: 0002008212-26-000002 · wk-form4_1767736023.xml · derivative · entry 1

Cox Christopher Nixon · CIK 0002008212 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,189

Underlying: Common Stock · 7,189 shares

Expires 2036-01-01

F2 · price: This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer fees of $85,000.

F1 · derivative.exercise_date: 1,797 shares underlying the option shall vest on March 31, 2026, 1,797 shares underlying the option shall vest on June 30, 2026, 1,798 shares underlying the option shall vest on September 30, 2026 and 1,797 shares underlying the option shall vest on December 31, 2026, subject to the Reporting Person's continuous service through each such vesting date.

Read SEC document
May 13, 2025 Filed May 15, 2025 20:16 UTC Alto Neuroscience, Inc. ANRO · Entity 4755 GrantStock Option (right to buy) · Derivative 15,287 $0.00 Strike: $2.37 $0.00
Disclosure

SEC source: 0001999480-25-000040 · wk-form4_1747340192.xml · derivative · entry 1

Cox Christopher Nixon · CIK 0002008212 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,287

Underlying: Common Stock · 15,287 shares

Expires 2035-05-12

F2 · price: The derivative securities were granted to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities.

F1 · derivative.exercise_date: The shares underlying the option shall vest on the earlier of the one-year anniversary of the date of grant and the date of Issuer's next Annual Meeting following the date of grant, subject to the Reporting Person's continuous service through such vesting date.

Read SEC document
March 28, 2025 Filed Apr 4, 2025 10:18 UTC Newsmax Inc. NMAX · Entity 789 GrantOption (Right to Buy) · Derivative 17,500 $0.00 Strike: $10.00 $0.00
Disclosure

SEC source: 0001213900-25-028778 · ownership.xml · derivative · entry 1

Cox Christopher Nixon · CIK 0002008212 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,500

Underlying: Common Stock · 17,500 shares

Expires 2035-03-28

F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's 2025 Omnibus Equity Incentive Plan and a Stock Option Grant Notice and Option Agreement. The option shall become exercisable on the 12-month anniversary of the grant date, provided that the Reporting Person continues to provide services to the Issuer through such date.

Read SEC document
January 02, 2025 Filed Jan 6, 2025 21:17 UTC Alto Neuroscience, Inc. ANRO · Entity 4755 GrantStock Option (right to buy) · Derivative 25,236 $3.17 Strike: $4.38 $79,998.12
Disclosure

SEC source: 0001999480-25-000004 · wk-form4_1736198217.xml · derivative · entry 1

Cox Christopher Nixon · CIK 0002008212 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,236

Underlying: Common Stock · 25,236 shares

Expires 2035-01-01

F2 · price: This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer fees of $80,000.

F1 · derivative.exercise_date: 6,309 shares underlying the option shall vest on each of March 31, 2025, June 30, 2025, September 30, 2025 and December 31, 2025, subject to the Reporting Person's continuous service through each such vesting date.

Read SEC document
February 06, 2024 Filed Feb 7, 2024 21:39 UTC Alto Neuroscience, Inc. ANRO · Entity 4755 ConversionSeries C Preferred Stock · Derivative 281,917 $0.00 $0.00
Disclosure

SEC source: 0001415889-24-002938 · form4-02072024_090202.xml · derivative · entry 4

Cox Christopher Nixon · CIK 0002008212 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Lightswitch Capital Fund I, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 126,755 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each share of Series C Preferred Stock was convertible at any time, at the holder's election, and automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering on a 2.2241 for 1 basis and has no expiration date.

F3 · derivative.exercise_date: Each share of Series C Preferred Stock was convertible at any time, at the holder's election, and automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering on a 2.2241 for 1 basis and has no expiration date.

F3 · derivative.expiration_date: Each share of Series C Preferred Stock was convertible at any time, at the holder's election, and automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering on a 2.2241 for 1 basis and has no expiration date.

F2 · ownership.nature: The shares are directly held by Lightswitch Capital Fund I, L.P. ("Lightswitch Capital"), of which Lightswitch Capital GP, LLC ("Lightswitch GP") is the sole general partner and exercises voting and investment power over these shares. The Reporting Person is the Chief Executive Officer of Lightswitch GP and disclaims beneficial ownership of these securities, except to the extent of his proportionate pecuniary interest therein.

Read SEC document
February 06, 2024 Filed Feb 7, 2024 21:39 UTC Alto Neuroscience, Inc. ANRO · Entity 4755 ConversionSeries B Preferred Stock · Derivative 1,250,000 $0.00 $0.00
Disclosure

SEC source: 0001415889-24-002938 · form4-02072024_090202.xml · derivative · entry 3

Cox Christopher Nixon · CIK 0002008212 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Lightswitch Capital Fund I, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 588,898 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series B Preferred Stock was convertible at any time, at the holder's election, and automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering on a 2.1226069 for 1 basis and had no expiration date.

F1 · derivative.exercise_date: Each share of Series B Preferred Stock was convertible at any time, at the holder's election, and automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering on a 2.1226069 for 1 basis and had no expiration date.

F1 · derivative.expiration_date: Each share of Series B Preferred Stock was convertible at any time, at the holder's election, and automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering on a 2.1226069 for 1 basis and had no expiration date.

F2 · ownership.nature: The shares are directly held by Lightswitch Capital Fund I, L.P. ("Lightswitch Capital"), of which Lightswitch Capital GP, LLC ("Lightswitch GP") is the sole general partner and exercises voting and investment power over these shares. The Reporting Person is the Chief Executive Officer of Lightswitch GP and disclaims beneficial ownership of these securities, except to the extent of his proportionate pecuniary interest therein.

Read SEC document
February 06, 2024 Filed Feb 7, 2024 21:39 UTC Alto Neuroscience, Inc. ANRO · Entity 4755 ConversionCommon Stock 126,755 Not disclosed Not disclosed
Disclosure

SEC source: 0001415889-24-002938 · form4-02072024_090202.xml · nonDerivative · entry 2

Cox Christopher Nixon · CIK 0002008212 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Lightswitch Capital Fund I, L.P.

Disclosed balance after: 715,653

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: Each share of Series C Preferred Stock was convertible at any time, at the holder's election, and automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering on a 2.2241 for 1 basis and has no expiration date.

F2 · ownership.nature: The shares are directly held by Lightswitch Capital Fund I, L.P. ("Lightswitch Capital"), of which Lightswitch Capital GP, LLC ("Lightswitch GP") is the sole general partner and exercises voting and investment power over these shares. The Reporting Person is the Chief Executive Officer of Lightswitch GP and disclaims beneficial ownership of these securities, except to the extent of his proportionate pecuniary interest therein.

Read SEC document
February 06, 2024 Filed Feb 7, 2024 21:39 UTC Alto Neuroscience, Inc. ANRO · Entity 4755 ConversionCommon Stock 588,898 Not disclosed Not disclosed
Disclosure

SEC source: 0001415889-24-002938 · form4-02072024_090202.xml · nonDerivative · entry 1

Cox Christopher Nixon · CIK 0002008212 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Lightswitch Capital Fund I, L.P.

Disclosed balance after: 588,898

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series B Preferred Stock was convertible at any time, at the holder's election, and automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering on a 2.1226069 for 1 basis and had no expiration date.

F2 · ownership.nature: The shares are directly held by Lightswitch Capital Fund I, L.P. ("Lightswitch Capital"), of which Lightswitch Capital GP, LLC ("Lightswitch GP") is the sole general partner and exercises voting and investment power over these shares. The Reporting Person is the Chief Executive Officer of Lightswitch GP and disclaims beneficial ownership of these securities, except to the extent of his proportionate pecuniary interest therein.

Read SEC document
February 01, 2024 Filed Feb 5, 2024 21:42 UTC Alto Neuroscience, Inc. ANRO · Entity 4755 GrantStock Option (right to buy) · Derivative 4,623 $11.88 Strike: $16.00 $54,939.73
Disclosure

SEC source: 0001415889-24-002558 · form4-02052024_090258.xml · derivative · entry 2

Cox Christopher Nixon · CIK 0002008212 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,623

Underlying: Common Stock · 4,623 shares

Expires 2034-01-31

F3 · price: This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer fees of $55,000.

F2 · derivative.exercise_date: 840 shares underlying the option shall vest on March 31, 2024, and 1,261 shares underlying the option shall vest on each of June 30, 2024, September 30, 2024 and December 31, 2024, subject to the Reporting Person's continuous service through each such vesting date.

Read SEC document
February 01, 2024 Filed Feb 5, 2024 21:42 UTC Alto Neuroscience, Inc. ANRO · Entity 4755 GrantStock Option (right to buy) · Derivative 30,574 $0.00 Strike: $16.00 $0.00
Disclosure

SEC source: 0001415889-24-002558 · form4-02052024_090258.xml · derivative · entry 1

Cox Christopher Nixon · CIK 0002008212 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,574

Underlying: Common Stock · 30,574 shares

Expires 2034-01-31

F1 · derivative.exercise_date: The shares underlying the option shall vest in 36 equal monthly installments commencing on March 1, 2024, subject to the Reporting Person's continuous service through each vesting date.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.